How to Find the Right Small Molecule CDMO

“Small molecule CDMO” describes a very large and diverse group of manufacturers.

One may specialize in early process chemistry.

Another may focus on large-scale API production.

Others may provide formulation, oral solid dose manufacturing, analytical development, highly potent manufacturing, or an integrated set of services.

So simply finding companies that work with small molecules does not narrow the market very far.

The real sourcing question is:

Which small molecule CDMOs appear suited to the chemistry, scale, stage, and manufacturing scope of this program?

A small molecule CDMO supports development or manufacturing of small molecule pharmaceutical products.

Depending on the company, services may include:

• route development
• process chemistry
• process optimization
• analytical development
• API manufacturing
• intermediate manufacturing
• scale-up
• technology transfer
• formulation development
• drug product manufacturing
• stability testing
• packaging
• clinical supply
• commercial manufacturing

A sponsor may use one organization for the entire workflow or work with separate API and drug product partners.

One of the first distinctions is whether the sponsor is sourcing:

API manufacturing

drug product manufacturing

or

both

An API CDMO may focus heavily on chemistry, process development, intermediates, and active ingredient production.

A drug product CDMO may focus on formulation and production of the final dosage form.

Some organizations provide both.

Before comparing companies, define the actual manufacturing scope.

Small molecule manufacturing is not one uniform capability.

Different processes can involve very different chemistry, equipment, containment requirements, materials, temperatures, pressures, solvents, and technical challenges.

Sponsors should understand which aspects of the process are likely to affect CDMO fit.

Questions may include:

• Is the route established?
• Is process development still required?
• Are specialized reaction conditions involved?
• Are there challenging intermediates?
• Are hazardous materials involved?
• Does the process require specialized containment?
• What scale has been demonstrated?

The relevant chemistry should guide the manufacturing search.

An early program may need significant work before the process is ready for GMP manufacturing.

That can include:

• route optimization
• reaction optimization
• impurity control
• crystallization development
• isolation strategy
• analytical methods
• scale-up
• process safety work

A sponsor with an established commercial process may need a very different CDMO from a team still developing its synthetic route.

The remaining development work should therefore be part of the selection criteria.

Scale can change the manufacturing challenge considerably.

A CDMO that is well suited to gram or kilogram development work may not be the preferred partner for much larger production.

Likewise, a large commercial facility may not be the most efficient fit for an early-stage program.

Sponsors should investigate:

• available reactor sizes
• practical batch ranges
• development scale
• clinical manufacturing scale
• commercial production capabilities

The goal is not automatically to maximize scale.

It is to select a manufacturing environment appropriate for the program.

Some small molecule programs require specialized containment because of potency or occupational exposure considerations.

If the compound requires a high-containment environment, that becomes a major sourcing criterion.

Sponsors may need to investigate:

• containment infrastructure
• material handling
• equipment configuration
• cleaning procedures
• exposure-control capabilities
• relevant manufacturing experience

A general small molecule capability statement does not necessarily mean a facility can support a high-potency program.

For sponsors looking beyond API manufacturing, dosage-form capability becomes important.

Small molecule drug product manufacturing can include forms such as:

• tablets
• capsules
• powders
• liquids
• other oral or specialized formulations

The sponsor should consider formulation needs, manufacturing scale, equipment, packaging requirements, and development stage.

If formulation development is still underway, development capabilities may matter as much as production capacity.

Not every small molecule translates easily into a practical dosage form.

Poor solubility, stability, bioavailability, or other formulation challenges may require additional development.

In those cases, a sponsor may prefer a CDMO with meaningful formulation expertise rather than selecting a partner based only on manufacturing infrastructure.

The manufacturing partner may need to help determine how the compound should ultimately be delivered.

Analytical work is closely tied to small molecule development and manufacturing.

Depending on the program, the sponsor may require support with:

• identity
• purity
• impurities
• residual solvents
• assay
• stability
• dissolution
• release testing

Sponsors should understand which analytical activities are handled internally and whether the proposed setup aligns with the development and manufacturing plan.

Two small molecule CDMOs can offer similar services while operating very different facilities.

Equipment and facility configuration can affect whether the process is practical.

Sponsors should investigate the manufacturing site expected to handle the project and, where relevant, the equipment that supports the proposed process.

This is especially important when the chemistry has unusual requirements.

An early development program may need:

• flexible batch sizes
• process-development support
• rapid iteration
• analytical development
• close technical collaboration

A commercial program may emphasize:

• process robustness
• supply reliability
• larger scale
• validated processes
• operational consistency

CDMO selection should reflect the current maturity of the program.

Small molecule CDMO diligence should include appropriate review of the proposed manufacturing facility.

That can include available regulatory information such as FDA Form 483 history where relevant.

Regulatory records should be evaluated in context.

A Form 483 does not automatically make a facility unsuitable, and absence of one does not eliminate the need for formal quality diligence.

A facility can support the chemistry and still be unable to meet the required timeline.

Once technical relevance has been established, sponsors should ask about:

• development start
• technology transfer
• raw-material lead times
• engineering work
• GMP production windows
• analytical timelines
• follow-on manufacturing

Capacity information can change quickly and should be verified directly with the CDMO.

A consistent framework makes it easier to distinguish meaningful differences between potential partners.

Outreach is more productive when the sponsor can describe the program clearly. Useful information to have ready includes:

• whether the need is API, drug product, or both
• a summary of the chemistry and current route
• process maturity and the most recent scale achieved
• potency and containment considerations
• the intended dosage form, if drug product is in scope
• target timing, quantities, and development stage

PCN helps sponsors define whether they need drug substance, drug product, or both, then compare relevant facilities on chemistry capabilities, equipment, scale, and regulatory context. Drug substance sourcing is covered in more depth in the API CDMO guide, and drug product sourcing in the oral solid dose CDMO guide.

Once a manufacturer appears relevant, the sponsor can request a structured introduction. Technical feasibility and capacity still need to be confirmed with the CDMO.